权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Combating melanoma resistance by targeting ABL1/2

通过靶向 ABL1/2 对抗黑色素瘤耐药性

基本信息

批准号：
10626076
负责人：
JILL MARIE KOLESAR
金额：
$ 57.15万
依托单位：
UNIVERSITY OF KENTUCKY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-05-23 至 2027-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10626076
关键词：
ABL1 gene Animal Model Animals BRAF gene Basic Science Biochemical Biological Cell Line Cells Cessation of life Clinical Clinical Trials Coculture Techniques Collaborations Conditioned Culture Media Coupling Data Dose Dose Limiting Drug Kinetics Drug resistance ERBB2 gene ERBB3 gene Experimental Designs FDA approved Family Flow Cytometry Genetically Engineered Mouse Goals Growth Factor Hematologic Neoplasms Immune Immunotherapeutic agent Immunotherapy In Vitro Incidence Intervention Invaded Kentucky Link MAP3K1 gene MEKs Maintenance Malignant Neoplasms Manuscripts Mass Spectrum Analysis Mediating Melanoma Cell Metastatic Melanoma Modeling Molecular Monitor Mutation Neoplasm Metastasis Oncologist PI3K/AKT Pathway interactions Patients Pharmaceutical Preparations Pharmacodynamics Phase Phase I/II Clinical Trial Phase I/II Trial Phosphotransferases Protein Family Protein Secretion Protein Tyrosine Kinase Proteomics Proto-Oncogene Proteins c-akt Publishing Qualifying RELA gene RNA Interference Recommendation Records Refractory Regimen Relapse Research Research Personnel Resistance Resistance development Role Safety Sampling Series Serum Serum Proteins Site Survival Rate Testing Toxic effect Translational Research Treatment Protocols Tumor Burden Xenograft procedure advanced disease antileukemic agent arm biomarker development chemokine cytokine drug-sensitive early phase clinical trial effective therapy experimental study gain of function human tissue immune cell infiltrate immunoregulation improved in vivo in vivo Model inhibitor innovation interdisciplinary approach loss of function melanoma mutant next generation sequencing novel open label patient subsets pharmacokinetics and pharmacodynamics pharmacologic phase 2 study prevent primary endpoint randomized, clinical trials resistance mechanism response safety testing secondary endpoint single-cell RNA sequencing targeted agent therapy resistant transcriptome sequencing translational goal tumor tumor-immune system interactions

项目摘要

SUMMARY Despite treatment advances over the past decade, five-year survival rates for metastatic melanoma remain low (23%). BRAF mutations occur in 50-75% of melanoma, and a combination of BRAF and MEK inhibitors (BRAFi, MEKi) are effective therapies; however, acquired resistance rapidly develops for most patients. Research over the past decade has identified mechanisms by which melanoma cells develop resistance to BRAF/MEK inhibitors, but thus far, there are no FDA-approved regimens that reverse BRAFi/MEKi resistance and increase the 5-year survival rate. Here, we demonstrate that the activities of the ABL family of non-receptor tyrosine kinases are potentiated following BRAFi or BRAFi/MEKi resistance, and ABL1/2 drive resistance. Moreover, targeting ABL1/2 with an FDA-approved anti-leukemia drug, nilotinib, dramatically reverses BRAFi/MEKi (dabrafenib/trametinib) resistance, in vivo, inducing prolonged tumor regression. Based on these exciting findings, the central hypothesis of our proposal is that ABL1/2 are key nodes that activate ERK-dependent or -independent pathways to drive BRAFi/MEKi resistance; thus, targeting ABL1/2 may be effective for overcoming resistance and ultimately extending survival for patients with treatment-refractory melanomas. Our long-term, translational goal is to develop a novel regimen to improve the 5-year survival rate for patients with metastatic melanoma. We propose a comprehensive hypothesis-driven experimental design and multi-disciplinary approach. Aim 1 will define mechanisms by which ABL1/2 drive resistance. To achieve our objective, biochemical, molecular biological and cell biological approaches using parental/resistant melanoma cell lines, pharmacological inhibitors/RNAi, mass spectrometry, xenograft, GEM, PDX, and syngeneic in vivo approaches, as well as human tissue collected from the clinical trial (Aim 3) will be used to test the hypothesis that ABL1/2 drive MAP3K activation of MEK/ERK/MYC (ERK-dependent resistance); induce ERBB2/ERBB3 activation of PI3K/AKT (ERK-independent resistance); and alter immune cell infiltration. In Aim 2, conditioned medium from parental/resistant cell lines, co-culture experiments using in vitro and in vivo models, and serum collected from animals and patients will be used to test the prediction that the ABL1/2-driven secretome contributes to BRAFi/MEKi resistance. Finally, Aim 3 is a multi-site, seamless Phase I/II clinical trial that tests the safety of combining nilotinib with dabrafenib+trametinib (BRAFi/MEKi) for treatment-refractory patients. Additional endpoints include identifying the recommended Phase II dose, initial efficacy (PFS) based on Phase II data, PK/PD studies, and initial exploratory biomarker development. Results from these studies not only will increase our understanding for how melanomas resist the effects of BRAFi/MEKi but also will lay the groundwork for a large, multi-center, randomized clinical trial.

总结